Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
APVO436 for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new drug, APVO436, to see if it is safe and effective in treating patients with AML or MDS. The primary objective of the Phase 1 part of the study is to determine the recommended dose of APVO436 administered intravenously to patients with AML or MDS. The primary objective of the Phase 1b part of the study is to evaluate the clinical activity of APVO436 in patients with AML or MDS.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service